We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 13, 2021

Zanubrutinib, Obinutuzumab, and Venetoclax With MRD-Driven Discontinuation in Previously Untreated Patients With CLL or Small Lymphocytic Lymphoma

The Lancet Haematology

 

Additional Info

The Lancet Haematology
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Lancet Haematol 2021 Dec 01;8(12)e879-e890, JD Soumerai, AR Mato, A Dogan, VE Seshan, E Joffe, K Flaherty, J Carter, E Hochberg, JA Barnes, AM Hamilton, JS Abramson, CL Batlevi, MJ Matasar, A Noy, CN Owens, ML Palomba, A Kumar, T Takvorian, A Ni, M Choma, C Friedman, P Chadha, E Simkins, J Ruiters, S Sechio, D Portman, L Ramos, N Nolet, N Mahajan, R Martignetti, J Mi, K Scorsune, J Lynch, B McGree, S Hughes, C Grieve, LE Roeker, M Thompson, PC Johnson, M Roshal, J Huang, J Biondo, Q Wu, A Jacob, O Abdel-Wahab, AD Zelenetz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading